This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer’s disease

Authors

Bahl, Justyna Maria Czarna, Heegaard, Niels H.H., Falkenhorst, Gerhard, Laursen, Henning, Høgenhaven, Hans, Mølbak, Kåre, Jespersgaard, Cathrine, Hougs, Lotte, Waldemar, Gunhild, Johannsen, Peter, Christiansen, Michael

Journal

Neurobiology Of Aging, Volume: 30, No.: 11, Pages.: 1834-1841

Year of Publication

2009

Abstract

Laboratory markers have a prominent place among the diagnostic criteria for sporadic Creutzfeldt-Jakob disease (sCJD). Here we investigate the capability of protein 14-3-3, total-tau (t-tau), threonin-181-phosphorylated tau (p-tau), and neuron-specific enolase (NSE) in cerebrospinal fluid (CSF) together with the prion protein gene genotype to discriminate patients with sCJD (n=21) from neurological controls (n=164) and Alzheimer’s disease (AD) patients (n=49). Low p-tau/t-tau ratio was the best single marker for sCJD with 90% specificity against neurological controls at 86% sensitivity whilst NSE was the least accurate with 79% sensitivity at 90% specificity. Many of the sCJD patients had extremely elevated t-tau values but normal values of the AD-marker p-tau. Protein 14-3-3 was very sensitive (95%) although the specificity was relatively low (75%). A combination of elevated t-tau concentration with the presence of 14-3-3 protein in CSF gave the best test specificity of 96% at 84% sensitivity. We conclude that the combination of more than one CSF marker for neurodegeneration can improve the diagnostic test accuracy for sCJD against neurological controls including patients with other dementias.;

Bibtex Citation

@article{Bahl_2009, doi = {10.1016/j.neurobiolaging.2008.01.013}, url = {http://dx.doi.org/10.1016/j.neurobiolaging.2008.01.013}, year = 2009, month = {nov}, publisher = {Elsevier {BV}}, volume = {30}, number = {11}, pages = {1834--1841}, author = {Justyna Maria Czarna Bahl and Niels H.H. Heegaard and Gerhard Falkenhorst and Henning Laursen and Hans H{o}genhaven and K{aa}re M{o}lbak and Cathrine Jespersgaard and Lotte Hougs and Gunhild Waldemar and Peter Johannsen and Michael Christiansen}, title = {The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer{textquotesingle}s disease}, journal = {Neurobiology of Aging} }

Keywords

1433 proteins, alzheimer disease, biological markers, cerebrospinal fluid, creutzfeldtjakob, creutzfeldtjakob syndrome, diagnosis, disease, genetics, humans, phosphopyruvate hydratase, prions, statistics nonparametric, tau proteins

Countries of Study

Denmark

Types of Dementia

Alzheimer’s Disease

Types of Study

Case Control Study

Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Genetic Testing